Listen on the go
    • Faculty & Disclosures
    Dr Anna Blakney

    University of British Columbia, Vancouver, BC, Canada

    Dr Anna Blakney is an assistant professor and Tier 2 Canada Research Chair in the Michael Smith Laboratories and School of Biomedical Engineering at the University of British Columbia (UBC), Vancouver, BC, Canada. read more

    Dr Blakney’s research background encompasses the development of molecular and biomaterial engineering strategies for delivery of self-amplifying RNA. Her lab uses bioengineering, molecular biology and immunology approaches to develop the next generation of RNA vaccines and therapies. Her research has been published in a variety of top tier journals including ACS Nano, Nature Communications, Molecular Therapy, Biomaterials, Journal of Controlled Release and Advanced Materials. Dr Blakney has received numerous awards and recognitions in addition to the Tier 2 Canada Research Chair in Nucleic Acid Bioengineering, including the 2022 Gairdner Early Career Investigator Award, the 2021 UBC President’s Award for Public Education Through Media and the 2022 Controlled Release Society Gene Delivery and Editing Focus Group Young Investigator Award.

    Dr Anna Blakney discloses: Advisory board or panel fees from GenVax. Grants/research support from Pfizer and Replicate Bioscience. Contractual service fees from Moderna (Relationship Terminated).
    Prof. Dr. med. Oliver Cornely

    University of Cologne, Germany

    Prof. Dr. med. Oliver Cornely is director and chair of Translational Research at the Cologne Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases at the University of Cologne, and scientific director of the Center for Clinical Trials. Clinically, he serves as infectious diseases consultant at the University Hospital of Cologne, Germany. read more

    Prof. Dr. med. Cornely is board certified in internal medicine, infectious diseases, haematology, oncology and emergency medicine, and holds degrees in medical mycology and travel medicine. In January 2021, he founded the VACCELERATE platform, which currently includes 23 countries and 29 partner institutions for the European Commission to accelerate vaccine development against COVID-19 and future pandemic pathogens.

    Prof. Dr. med. Cornely is immediate-past president of the European Confederation of Medical Mycology (ECMM), the umbrella organization of 28 national mycology societies. He set up the ECMM Global Guideline programme, ECMM Academy (Fellows programme), and ECMM Excellence Center Initiative, designating clinical and microbiological excellence centres after an international audit procedure. He is founder and chair of the Infectious Diseases Scientific Working Group of the European Hematology Association. Prof. Dr. med. Cornely is a member of the Council of the International Society for Human and Animal Mycology and serves as chair of the Infectious Diseases Working Party, a working group of the German Society for Hematology and Oncology. He was recently elected as site spokesman for Bonn/Cologne for the German Center for Infection Research.

    Prof. Dr. med. Oliver Cornely discloses: Grant Research and Support from Amplyx, Basilea, BMBF, Cidara, DZIF, Gilead, Matinas, MedPace, MSD, Mundipharma, Pfizer and Scynexis. Consulting fees from Abbvie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC and Pfizer. Speaker’s Bureau from Abbott, Abbvie, Al-Jazeera Pharmaceuticals, Astellas, Gilead, Grupo Biotoscana, Hikma, MedUpdate, Merck/MSD, Mylan, Noscendo and United Medical/Knight. Expert testimony from Cidara. Data Safety Monitoring Board or Advisory Board from Actelion, Cidara, Entasis, IQVIA, Janssen, Med Pace, Paratek, Pulmocide and Shionogi. Other from DZIF – German Center for Infection Research.
    Prof. Ann R Falsey

    University of Rochester School of Medicine, New York, NY, USA

    Prof. Ann R Falsey is a professor of medicine at the University of Rochester School of Medicine, New York, NY, USA. read more

    Prof. Falsey is well established in clinical and translational research in the field of respiratory viral infections in adults, including: the epidemiology and impact of respiratory syncytial virus in adult populations, influenza, coronaviruses, parainfluenza viruses and human metapneumovirus. She has conducted numerous adult surveillance and vaccine studies in a variety of settings, including ambulatory older adult clinics, nursing homes and senior daycare centres. She has extensive experience in diagnostic and serologic assay development for respiratory viruses.

    Prof. Falsey is a member of the steering committee for the Global Influenza Initiative, the Infectious Diseases Society of America and the American Virology Society. She has published over 200 peer-reviewed articles, reviews, book chapters and abstracts. She currently serves as the co-director for the National Institute of Allergy and Infectious Diseases Respiratory Pathogens Research Center recently awarded to the University of Rochester. 

    Prof. Ann R Falsey discloses: Advisory board or panel fees from Sanofi. Consultancy fees from Gilead. Grants/research support from BioFire Diagnostics, CyanVac, Janssen, Merck, Moderna and Pfizer.
    Downloads
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    CORRECT!
    Next question
    touchINFECTIOUS DISEASES touchINFECTIOUS DISEASES
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:

    • Vaccines

    International Partner

    An Introduction to Vaccines

    Vaccines have substantially reduced morbidity and mortality from infectious diseases in the developed world. Many vaccines, including those for measles and some influenza vaccines, use live attenuated viruses. The COVID-19 pandemic has led to unprecedented rates of vaccine development, raising hopes that other vaccines might be made on a comparable timescale in the future. In particular, it has established the clinical utility of mRNA vaccines,
    which have demonstrated high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. In addition, other approaches, including nucleic acid-based vaccines, recombinant DNA platforms, virus-like particle (VLP) based vaccines, non-replicating viral vectors, recombinant nanoparticles and peptide vaccines in active clinical development.

    Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Vaccines Content

    COVID-19, Vaccines, Respiratory Infections
    Watch Time: 32 mins
    touchEXPERT OPINIONS
    The mRNA vaccine platform: A novel tool for the rapid development of vaccines against respiratory viral infections
    CE/CME ACCREDITED Dr Anna Blakney, Prof. Dr. med. Oliver Cornely, Prof. Ann R Falsey Translations available:

    Leading experts explore mRNA vaccine platforms for respiratory viruses, including their design, clinical application and future prospects.

    Learning objectives
    Learning Objectives
    • Recognize the rationale for mRNA-based vaccines and considerations for their design
    • Discuss the effectiveness of mRNA-based vaccines to manage respiratory viral diseases based on clinical and real-world experiences with COVID-19 vaccines
    • Discuss recent developments in the use of the mRNA platform to develop prophylactic and therapeutic vaccines for respiratory diseases
    Vaccines, Sexually Transmitted Infections, Viral Infections
    Watch Time: 35 mins
    touchPANEL DISCUSSION
    Preventing HPV-associated cancer by maximizing vaccine uptake
    CE/CME ACCREDITED Prof. Lynette Denny GCOB (Silver), Prof. Eduardo Franco OC, Prof. Daniel Kelly OBE

    Watch three experts discuss the importance of HPV vaccination in preventing HPV-associated cancers, and how to maximize vaccine uptake

    Learning objectives
    Learning Objectives
    • Illustrate the importance of vaccinating children and adolescents against HPV to prevent cancer in adulthood
    • Describe recent guidelines and best practices for HPV vaccine eligibility and administration
    • Appraise the barriers to HPV vaccine uptake in different populations and how they may be overcome
    Hepatitis, Vaccines
    Developed by Touch
    The first mass reactive vaccination campaign against hepatitis E in Bentiu, South Sudan: Iza Ciglenecki, EASL 2023
    Watch Time: 5 mins

    Since 2015, cases of hepatitis E have been reported in the Bentiu camp in South Sudan, Africa, which hosts over 100,000 people displaced from conflict and flooding. The first mass reactive vaccination campaign against hepatitis E using the Hecolin® vaccine, the key findings of the campaign and unanswered questions, are discussed by Dr Iza Ciglenecki […]

    Hepatitis, Vaccines
    Developed by Touch
    The Hecolin® vaccine in the prevention of hepatitis E: Iza Ciglenecki, EASL 2023
    Watch Time: 2 mins

    A three-dose recombinant vaccine (Hecolin®) against hepatitis E has been licensed in China since 2011. We caught up with Dr Iza Ciglenecki (Médecins Sans Frontières, Geneva, Switzerland) to discuss the prognosis and treatment paradigm for hepatitis E, the challenges associated with optimizing hepatitis E vaccine efficacy and reducing the burden of disease, and what is […]

    COVID-19, Vaccines, Viral Infections, Respiratory Infections
    Watch Time: 37 mins
    touchIN CONVERSATION
    Practical considerations for COVID-19 vaccination in the Middle East
    CE/CME ACCREDITED Dr Farhan Fazal, Dr Nada Melhem Translations available:

    Watch experts in infectious diseases discuss COVID-19 vaccination challenges and strategies for improving vaccine uptake in the Middle East.

    Learning objectives
    Learning Objectives
    • Outline the benefits and risks associated with COVID-19 vaccines
    • Identify reasons for low COVID-19 vaccine uptake in the Middle East
    • Discuss approaches to increase COVID-19 vaccine uptake, with a focus on the role of healthcare workers
    COVID-19, Vaccines, Viral Infections, Respiratory Infections
    Watch Time: 40 mins
    touchIN CONVERSATION
    Practical considerations for COVID-19 vaccination in Africa
    CE/CME ACCREDITED Dr Christina Obiero, Dr John Amuasi Translations available:

    Watch experts in infectious diseases discuss COVID-19 vaccination challenges and strategies for improving vaccine uptake in Africa.

    Learning objectives
    Learning Objectives
    • Outline the benefits and risks associated with COVID-19 vaccines
    • Identify reasons for low COVID-19 vaccine uptake in Africa
    • Discuss approaches to increase COVID-19 vaccine uptake, with a focus on the role of healthcare workers
    COVID-19, Vaccines, Viral Infections, Respiratory Infections
    Watch Time: 59 mins
    touchPANEL DISCUSSION
    Reducing transmission of COVID-19: Spotlight on vaccines
    CE/CME ACCREDITED Dr Angus Thomson, Dr Amaya Gillespie, Dr Henry Kyobe Bosa Translations available:

    A series of expert panel discussions providing multiple perspectives on a selection of key topics and what the data may mean for clinical practice

    Learning objectives
    Learning Objectives
    • Summarize the current COVID-19 vaccination landscape
    • Identify factors contributing to differential uptake of COVID-19 vaccines in population subsets
    • Evaluate strategies to improve COVID-19 vaccine uptake
    • Discuss the future of COVID-19 vaccination, including how vaccine inequity may be addressed
    COVID-19, Vaccines
    Developed by Touch
    PHH-1V vaccine compared to BNT162b2 as a SARS-CoV-2 booster vaccine, phase IIb results: Patricia Muñoz García, ECCMID 2023
    Watch Time: 6 mins

    PHH-1V, a SARS-CoV-2 protein-based heterodimer vaccine was investigated in a phase IIb trial where the immunogenicity and safety of a heterologous booster with PHH-1V was assessed versus a homologous booster with BNT162b2 at 14, 28 and 98 days after vaccine administration. We spoke with Prof. Patricia Muñoz García (Gregorio Marañón General University Hospital, Madrid, Spain) […]

    COVID-19, Vaccines
    Ruth Link-Gelles, IDWeek 2022: Efficacy of COVID-19 vaccination in paediatric populations
    Watch Time: 2 mins

    In this touchINFECTIOUS DISEASES interview, we met with Dr Ruth Link-Gelles (Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA) to discuss the incidence of COVID-19 in children, vaccine effectiveness against infection and disease severity, and the current status of paediatric COVID-19 vaccines in the United States. Interviews available in this series: Real world […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72